Full Breakdown
Trump Administration Poised to Reclassify Marijuana Under Federal Law
4/22/2026, 9:52:27 PM
Overview of the Reclassification Process
The Trump administration is expected to reclassify marijuana as a Schedule III drug under the Controlled Substances Act as early as April 22, 2026. This significant change would recognize cannabis as having accepted medical uses, aligning it with substances like ketamine and testosterone. The reclassification follows an executive order signed by President Donald Trump in December 2025, which aimed to expedite the process of loosening federal regulations surrounding marijuana.
Implications for the Cannabis Industry
Reclassifying marijuana could have profound implications for the cannabis industry, including easing restrictions on research and reducing tax burdens for cannabis businesses. Stocks of major cannabis companies, such as Canopy Growth and Tilray Brands, surged in response to the news, reflecting investor optimism about the potential for increased funding and market growth. The reclassification would also facilitate scientific studies into the medicinal applications of marijuana, which has been a contentious issue amid ongoing debates about its legality.
Official Statements & Responses
President Trump emphasized the need for this change, stating, “We have people begging for me to do this, people that are in great pain.” He noted that the executive order was a response to long-standing requests from patients suffering from various medical conditions. However, he clarified that the order does not legalize marijuana for recreational use, nor does it affect existing legal penalties for possession.
Criticism & Opposition
Despite the anticipated benefits, there is significant opposition to the reclassification. Groups such as Smart Approaches to Marijuana, led by Kevin Sabet, have expressed concerns about the potential for increased use and dependency. They have reportedly prepared legal challenges to contest the reclassification, with former Attorney General Bill Barr involved in these efforts. Additionally, 22 Republican senators have previously opposed the rescheduling of marijuana, indicating a potential for legal hurdles that could delay or complicate the process.
Conflicting Reports & Gaps
While reports indicate that the reclassification could happen imminently, there are uncertainties regarding the timeline and the legal challenges that may arise. The Drug Enforcement Administration (DEA) has faced delays in the rule-making process, and there are concerns about whether the administration will be able to navigate these obstacles effectively. A Polymarket contract suggests skepticism about whether the reclassification will occur by the end of June 2026, highlighting the complexities involved.
What's Next
As the administration moves forward, the next steps include finalizing the reclassification and addressing any legal challenges that may arise. The outcome of this process will not only affect the cannabis industry but could also influence public perception and future legalization efforts across the United States.
Verbatim Quotes
- “Today’s the day,” — Unnamed Trump administration official
- “It is the policy of my Administration to increase medical marijuana and CBD research to better inform patients and doctors,” — President Donald Trump
- “does not legalize marijuana in any way, shape or form, and no way sanctions its use as a recreational drug.” — President Donald Trump
